Citations

Clear

3314 citation(s) found for "Do, Alexander".

Bilateral Paragangliomas
Goranov, Nickolas , Alexander, Lauren F.

Mayo Clinic

No container title available | January 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20225952 Get It

International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers
Broman, Kristy K., Hughes, Tasha M., Bredbeck, Brooke C., Sun, James, Kirichenko, Dennis, Carr, Michael J., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda A.G., Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, Akkooi, Alexander van, Ollila, David W., O’shea, Kristin, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Hotz, Meghan, Farma, Jeffrey M., Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew, Baecher, Kirsten, Lowe, Michael, Bagge, Roger Olofsson, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Kroon, Hidde M., Teras, Juri, Teras, Roland M., Farrow, Norma E., Beasley, Georgia M., Hui, Jane Yuet Ching, Been, Lukas, Kruijff, Schelto, Sinco, Brandy, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S., Dossett, Lesly A., Hui, Jane Yuet Ching , Dossett, Lesly A. , Akkooi, Alexander C. J. van , Bagge, Roger Olofsson , Kroon, Hidde M. , Hui, Jane Yuet Ching , Olofsson Bagge, Roger , Broman, Kristy K., Hughes, Tasha M., Bredbeck, Brooke C. , Sun, James, Kirichenko, Dennis, Carr, Michael J., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda A.G., Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, Ollila, David W., O’shea, Kristin, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Hotz, Meghan, Farma, Jeffrey M., Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew, Baecher, Kirsten, Lowe, Michael, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Teras, Juri, Teras, Roland M., Farrow, Norma E., Beasley, Georgia M., Hui, Jane Yuet Ching, Been, Lukas, Kruijff, Schelto, Sinco, Brandy, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S.

Mayo Clinic

Annals of Surgery | January 29, 2022 | Volume: 277 | Issue: 5 | Pages: e1106-e1115

10.1097/sla.0000000000005370 | PMID 35129464 Get It

Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Data: Based on recent clinical trials, management options for SLN-positive melanoma now include effective adjuvant systemic therapy and nodal observation instead of CLND. It is unknown how these findings have shaped practice or how these contemporaneous developments have influenced their respective utilization. Methods: We performed an international cohort study at 21 melanoma referral centers in Australia, Europe, and the United States that treated adults with SLN-positive melanoma and negative distant staging from July 2017 to June 2019. We used generalized linear and multinomial logistic regression models with random intercepts for each center to assess center-level variation in CLND and adjuvant systemic treatment, adjusting for patient and disease-specific characteristics. Results: Among 1109 patients, performance of CLND decreased from 28% to 8% and adjuvant systemic therapy use increased from 29 to 60%. For both CLND and adjuvant systemic treatment, the most influential factors were nodal tumor size, stage, and location of treating center. There was notable variation among treating centers in management of stage IIIA patients and use of CLND with adjuvant systemic therapy versus nodal observation alone for similar risk patients. Conclusions: There has been an overall decline in CLND and simultaneous adoption of adjuvant systemic therapy for patients with SLN-positive melanoma though wide variation in practice remains. Accounting for differences in patient mix, location of care contributed significantly to the observed variation.
Impact of mitral intervention on outcomes of patients with mitral valve dysfunction and annulus calcification
Kato, Nahoko , Pellikka, Patricia A. , Lee, Alexander T., Jain, Vaibhav , Eleid, Mackram F. , Reeder, Guy S., Bagameri, Gabor, Rihal, Charanjit S. , Eleid, Mackram F , Alkhouli, Mohamad A, Guerrero, Mayra E , Pellikka, Patricia A , Scott, Christopher G. , Alkhouli, Mohamad , Michelena, Héctor I. , Pislaru, Sorin V. , Crestanello, Juan A. , Rihal, Charanjit S. , Guerrero, Mayra

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 23, 2022 | Volume: 99 | Issue: 6 | Pages: 1807-1816

10.1002/ccd.30093 | PMID 35066988 Get It

AbstractObjectivesTo compare all‐cause mortality in patients with mitral annulus calcification (MAC) and severe mitral valve dysfunction (MVD) who received standard mitral intervention versus no intervention.BackgroundPatients with MAC often have high surgical risk due to advanced age, comorbidities, and technical challenges related to calcium. The impact of a mitral intervention on outcomes of patients with MAC and severe MVD is not well known.MethodsRetrospective review of patients with MAC by transthoracic echocardiography (TTE) in 2015 at a single institution. Patients with severe mitral stenosis (MS) or regurgitation (MR) were analyzed and stratified into two groups: surgical or transcatheter intervention performed <1 year after the index TTE, and no or later intervention. The primary endpoint was all‐cause mortality.ResultsOf 5502 patients with MAC, 357 had severe MVD (MS = 27%, MR = 73%). Of those, 108 underwent mitral intervention (surgery = 87; transcatheter = 21). They were younger (73 ± 11 vs. 76 ± 11 years, p < 0.01) and less frequently had cardiovascular diseases compared with no‐intervention. Frequency in women was similar (45% vs. 50%, p = 0.44). During median follow‐up of 3.2 years, the intervention group had higher estimated survival than those without intervention (80% vs. 72% at 1 year and 55% vs. 35% at 4 year, p < 0.01). Adjusted for age, eGFR, LVEF < 50%, and pulmonary hypertension, mitral intervention was an independent predictor of lower mortality (hazard ratio = 0.66, 95% confidence interval 0.43–0.99, p = 0.046).ConclusionPatients with MAC and severe MVD who underwent mitral intervention <1 year from index TTE had lower mortality than those without intervention. Mitral intervention was independently associated with lower mortality.
AAPM Task Group Report 290: Respiratory motion management for particle therapy
Li, Heng , Flampouri, Stella , Jee, Kyung‐Wook , Lin, Liyong , Moyers, Michael F. , Rottmann, J, Tryggestad, E., Vedam, Sastry, Tryggestad, Erik, Lin, Liyong , Dong, Lei , Bert, Christoph , Chang, Joe Y. , Mori, Shinichiro

Mayo Clinic

Medical Physics | January 23, 2022 | Volume: 49 | Issue: 4 | Pages: No page available

10.1002/mp.15470 | PMID 35066871 Get It

Abstract Dose uncertainty induced by respiratory motion remains a major concern for treating thoracic and abdominal lesions using particle beams. This Task Group report reviews the impact of tumor motion and dosimetric considerations in particle radiotherapy, current motion‐management techniques, and limitations for different particle‐beam delivery modes (i.e., passive scattering, uniform scanning, and pencil‐beam scanning). Furthermore, the report provides guidance and risk analysis for quality assurance of the motion‐management procedures to ensure consistency and accuracy, and discusses future development and emerging motion‐management strategies. This report supplements previously published AAPM report TG76, and considers aspects of motion management that are crucial to the accurate and safe delivery of particle‐beam therapy. To that end, this report produces general recommendations for commissioning and facility‐specific dosimetric characterization, motion assessment, treatment planning, active and passive motion‐management techniques, image guidance and related decision‐making, monitoring throughout therapy, and recommendations for vendors. Key among these recommendations are that: (1) facilities should perform thorough planning studies (using retrospective data) and develop standard operating procedures that address all aspects of therapy for any treatment site involving respiratory motion; (2) a risk‐based methodology should be adopted for quality management and ongoing process improvement.
Surgical Management of Sacral Schwannomas: A 21-Year Mayo Clinic Experience and Comparative Literature Analysis
Ghaith, Abdul-Karim, Rush, Deja, Jarrah, R. Al, Alexander, Yohan, Zamanian, Cameron , Atkinson, John L. D., Yaszemski, Michael J. , Krauss, William E. , Spinner, Robert J. , Bydon, Mohamad , Mualem, William , Jarrah, Ryan

Mayo Clinic

No container title available | January 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1274638/v1 Get It

Abstract Introduction: Sacral and presacral schwannomas are rare and account for a minority of spinal schwannomas. We aim to present our institution’s experience surgically treating sacral schwannomas over twenty-one years. Additionally, we assess the literature for surgical cases of sacral schwannomas to compare tumor characteristics and outcomes following resection.Methods: Data on demographics, presenting symptoms, lesion characteristics, surgical management, and outcomes were collected for 27 patients treated surgically for sacral or presacral schwannoma between 1997 and 2018 at all Mayo Clinic locations and compared to those of patients found in the literature. Results: We identified 31 studies in the literature containing 93 patients with sacral schwannoma treated surgically. Our patients and those in the literature experienced similar symptoms, with the most common symptom being pain and the least common being sexual dysfunction, and age at diagnosis. Most of our patients (59.3%) reported full recovery from preoperative symptoms, while a minority reported a partial recovery (33.3%) and no recovery (11.1%). A smaller percentage of patients found in the literature experienced full recovery (31.9%) and partial recovery (29.8%) but also no recovery (1.1%). Our patients experienced fewer complications (14.8% versus 25.5%).Conclusion: Outcomes of patients with sacral or presacral schwannomas vary based on patient demographics, tumor characteristics, symptoms, and surgical treatment. Among the range of symptoms experienced by these patients, the most common is pain. Prognosis improves and overall survival rate is high when the surgical approach towards sacral schwannomas is prepared and executed appropriately.
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
Yaeger, Rona , Buchschacher, Gary L. , McRee, Autumn J. , Sabari, Joshua K. , Hafez, Navid , Velastegui, Karen , Christensen, James G. , Kheoh, Thian , Der‐Torossian, Hirak , Bekaii‐Saab, Tanios , Spira, Alexander I. , Johnson, Melissa L. , Barve, Minal , Rybkin, Igor I.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 519-519

10.1200/jco.2022.40.4_suppl.519 Get It

519 Background: KRAS, the most frequently mutated oncogene in cancer, is a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRAS mutations occur in approximately 90% of pancreatic cancer, and approximately 2% of these are KRASG12C mutations. Adagrasib, an investigational agent, is a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it in its inactive state; adagrasib has been optimized for favorable pharmacokinetic (PK) properties, including long half-life (̃24 h), extensive tissue distribution, dose-dependent PK, as well as CNS penetration. Methods: KRYSTAL-1 (NCT03785249) is a multicohort Phase 1/2 study evaluating adagrasib as monotherapy or in combinations in pts with advanced solid tumors harboring a KRASG12C mutation. Here we report preliminary data from pts enrolled in a Phase 2 cohort evaluating single-agent adagrasib administered orally at 600 mg BID in previously treated pts with unresectable or metastatic solid tumors (excluding NSCLC and CRC), including pancreatic and other GI cancers. Study endpoints include clinical activity, safety, and PK. Results: The data cutoff was 10 September 2021. A total of 42 pts were enrolled in this cohort (median age 63.5 years, range 21–89; 52% female; 71% white; 29%/71% ECOG PS 0/1; median 2 prior lines of therapy, range 1–7; median follow-up 6.3 months), of whom 30 pts had KRASG12C-mutant GI tumors (12 PDAC, 8 biliary tract, 5 appendiceal, 2 gastro-esophageal junction, 2 small bowel, and 1 esophageal). In a preliminary analysis, 27 pts with GI tumors were evaluable for clinical activity; partial responses (PRs) were seen in 41% (11/27, including 3 unconfirmed PRs); the disease control rate (DCR) was 100% (27/27). Of the 12 pts with PDAC (median 3 prior lines of therapy; median follow-up 8.1 months), 10 were evaluable for clinical activity; PRs were seen in 50% (5/10, including 1 unconfirmed PR); the DCR was 100% (10/10). Median progression-free survival (PFS) was 6.6 months (95% CI 1.0–9.7), and treatment was ongoing in 50% of pts with PDAC. Among the 17 evaluable pts with other GI tumors, 6 achieved PR (35%; 2 unconfirmed) with a DCR of 100% (17/17); 11 pts were still receiving treatment. In the overall cohort, treatment-related adverse events of any grade occurred in 91% (38/42), the most frequent being nausea (48%), diarrhea (43%), vomiting (43%), and fatigue (29%); grade 3/4 events occurred in 21% of pts, with no grade 5 events. Conclusions: Adagrasib monotherapy is well tolerated and demonstrates encouraging clinical activity in pretreated pts with PDAC and other GI tumors harboring a KRASG12C mutation. Further exploration of adagrasib is ongoing in this pt population (NCT03785249). Clinical trial information: NCT03785249.
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Kelley, Robin Kate , Furuse, Junji , Toni, Enrico N. De , Vasilyev, Alexander, Heurgué, Alexandra , Mody, Kabir , Thungappa, Satheesh Chiradoni, Negro, Alejandra , Abou‐Alfa, Ghassan K. , Chan, Stephen L. , Kudo, Masatoshi , Lau, George , Furuse, Junji , Sukeepaisarnjaroen, Wattana , Kang, Yoon‐Koo , Dao, Tu Van , Rimassa, Lorenza , Breder, Valeriy Vladimirovich , Tam, Vincent C. , He, Philip , Sangro, Bruno

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 379-379

10.1200/jco.2022.40.4_suppl.379 Get It

379 Background: A single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the STRIDE (Single T Regular Interval D) regimen, formerly T300+D, showed encouraging clinical activity and limited toxicity in a phase 2 uHCC study (Study 22, NCT02519348), suggesting single exposure to T is sufficient to improve upon D activity. HIMALAYA (NCT03298451) evaluated the efficacy and safety of STRIDE or D vs sorafenib (S) in uHCC. Methods: HIMALAYA is an open-label, multicenter, phase 3 study, in which pts with uHCC and no prior systemic therapy were initially randomized to STRIDE (T 300 mg plus D 1500 mg [one dose] plus D 1500 mg every 4 weeks [Q4W]), D (1500 mg Q4W), S (400 mg twice daily), or T 75 mg Q4W (4 doses) plus D 1500 mg Q4W (T75+D). Recruitment to T75+D ceased after a planned analysis of Study 22 showed T75+D did not meaningfully differ from D. The primary objective was overall survival (OS) for STRIDE vs S. The secondary objective was OS noninferiority (NI) of D to S (NI margin: 1.08). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR; RECIST v.1.1), duration of response (DoR), and safety. Results: In total, 1171 pts were randomized to STRIDE (N=393), D (N=389), or S (N=389). At data cutoff (DCO), the primary objective was met: OS was significantly improved for STRIDE vs S (hazard ratio [HR], 0.78; 96% confidence interval [CI], 0.65–0.92; p=0.0035; Table). D met the objective of OS NI to S (HR, 0.86; 96% CI, 0.73–1.03). ORRs were higher for STRIDE (20.1%) and D (17.0%) than for S (5.1%). No new safety signals were identified. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 25.8% (STRIDE), 12.9% (D), and 36.9% (S) of pts. Grade 3/4 hepatic TRAEs occurred in 5.9% (STRIDE), 5.2% (D), and 4.5% (S) of pts. No TRAE of esophageal varices hemorrhage occurred. Rates of TRAEs leading to discontinuation were 8.2% (STRIDE), 4.1% (D), and 11.0% (S). Conclusions: HIMALAYA was the first large phase 3 trial with a diverse, representative uHCC population and extensive long-term follow-up to assess both mono- and combination immunotherapy. D was noninferior to S with favorable safety. The combination of a single priming dose of T plus D in STRIDE displayed superior efficacy and a favorable benefit-risk profile vs S. STRIDE is a proposed, novel, first-line standard of care systemic therapy for uHCC. Clinical trial information: NCT03298451. [Table: see text]
Considerations for the Use of Phage Therapy in Clinical Practice
Suh, Gina A. , Lodise, Thomas P. , Tamma, Pranita D. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Barton, Karen D., Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J. , Sund, Zoe, Tyne, Daria Van , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Barton, Karen D. , van Duin, David , Van Tyne, Daria , Patel, Robin , Tamma, Pranita D , Suh, Gina A , Lodise, Thomas P. , Knisely, Jane M., Alexander, Jose, Aslam, Saima, Bizzell, Erica, Totten, Katherine M. C. , Campbell, Joseph L., Chan, Benjamin K., Cunningham, Scott A., Goodman, Katherine E., Greenwood-Quaintance, Kerryl E., Harris, Anthony D., Hesse, Shayla , Maresso, Anthony, Nussenblatt, Veronique, Pride, David , Rybak, Michael J , Sund, Zoe, Group, for the Antibacterial Resistance Leadership

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 18, 2022 | Volume: 66 | Issue: 3 | Pages: No page available

10.1128/aac.02071-21 | PMID 35041506 Get It

Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)
Lee, Seohyuk , Zhang, Sui , Ou, Fang‐Shu , Bainter, Tiffany M., Niedzwiecki, Donna , Whittom, Renaud , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Kindler, Hedy L. , Gross, Cary P. , Irwin, Melinda L. , Meyerhardt, Jeffrey A. , Fuchs, Charles S. , Ou, Fang-Shu , Kindler, Hedy , Meyerhardt, Jeffrey A , Niedzwiecki, Donna , Ma, Chao , Saltz, Leonard B. , Mayer, Robert J.

Mayo Clinic

The Oncologist | January 13, 2022 | Volume: 27 | Issue: 6 | Pages: e494-e505

10.1093/oncolo/oyab070 | PMID 35641198 Get It

Abstract Background Limited and conflicting findings have been reported regarding the association between social support and colorectal cancer (CRC) outcomes. We sought to assess the influences of marital status and living arrangement on survival outcomes among patients with stage III colon cancer. Patients and Methods We conducted a secondary analysis of 1082 patients with stage III colon cancer prospectively followed in the CALGB 89803 randomized adjuvant chemotherapy trial. Marital status and living arrangement were both self-reported at the time of enrollment as, respectively, married, divorced, separated, widowed, or never-married, and living alone, with a spouse or partner, with other family, in a nursing home, or other. Results Over a median follow-up of 7.6 years, divorced/separated/widowed patients experienced worse outcomes relative to those married regarding disease free-survival (DFS) (hazards ratio (HR), 1.44 (95% CI, 1.14-1.81); P =.002), recurrence-free survival (RFS) (HR, 1.35 (95% CI, 1.05-1.73); P = .02), and overall survival (OS) (HR, 1.40 (95% CI, 1.08-1.82); P =.01); outcomes were not significantly different for never-married patients. Compared to patients living with a spouse/partner, those living with other family experienced a DFS of 1.47 (95% CI, 1.02-2.11; P = .04), RFS of 1.34 (95% CI, 0.91-1.98; P = .14), and OS of 1.50 (95% CI, 1.00-2.25; P =.05); patients living alone did not experience significantly different outcomes. Conclusion Among patients with stage III colon cancer who received uniform treatment and follow-up within a nationwide randomized clinical trial, being divorced/separated/widowed and living with other family were significantly associated with greater colon cancer mortality. Interventions enhancing social support services may be clinically relevant for this patient population. Trial Registration ClinicalTrials.gov Identifier: NCT00003835
Death With Function and Graft Failure After Kidney Transplantation: Risk Factors at Baseline Suggest New Approaches to Management
Merzkani, Massini A., Bentall, Andrew J., Smith, Byron H., Lopez, Xiomara Benavides, D’Costa, Matthew R., Park, Walter D., Kremers, Walter K., Issa, Naim, Rule, Andrew D., Chakkera, Harini, Reddy, Kunam, Khamash, Hasan, Wadei, Hani M., Mai, Martin, Alexander, Mariam P., Amer, Hatem, Kukla, Aleksandra, Ters, Mireille El, Schinstock, Carrie A., Gandhi, Manish J., Heilman, Raymond, Stegall, Mark D., Kremers, Walter K. , Chakkera, Harini A. , Wadei, Hani M. , D’Costa, Matthew R. , Benavides Lopez, Xiomara, El Ters, Mireille, D'Costa, Matthew , Chakkera, Harini A , Wadei, Hani M , Kremers, Walter K , Merzkani, Massini A., Bentall, Andrew J., Smith, Byron H., Lopez, Xiomara Benavides, Park, Walter D., Issa, Naim, Rule, Andrew D., Reddy, Kunam, Khamash, Hasan, Mai, Martin, Alexander, Mariam P., Amer, Hatem, Kukla, Aleksandra, Ters, Mireille El, Schinstock, Carrie A., Gandhi, Manish J., Heilman, Raymond, Stegall, Mark D.

Mayo Clinic

Transplantation Direct | January 13, 2022 | Volume: 8 | Issue: 2 | Pages: e1273

10.1097/txd.0000000000001273 | PMID 35047660 Get It

Background. Improving both patient and graft survival after kidney transplantation are major unmet needs. The goal of this study was to assess risk factors for specific causes of graft loss to determine to what extent patients who develop either death with a functioning graft (DWFG) or graft failure (GF) have similar baseline risk factors for graft loss. Methods. We retrospectively studied all solitary renal transplants performed between January 1, 2006, and December 31, 2018, at 3 centers and determined the specific causes of DWFG and GF. We examined outcomes in different subgroups using competing risk estimates and cause-specific Cox models. Results. Of the 5752 kidney transplants, graft loss occurred in 21.6% (1244) patients, including 12.0% (691) DWFG and 9.6% (553) GF. DWFG was most commonly due to malignancy (20.0%), infection (19.7%), cardiac disease (12.6%) with risk factors of older age and pretransplant dialysis, and diabetes as the cause of renal failure. For GF, alloimmunity (38.7%), glomerular diseases (18.6%), and tubular injury (13.9%) were the major causes. Competing risk incidence models identified diabetes and older recipients with higher rates of both DWFG and nonalloimmune GF. Conclusions. These data suggest that at baseline, 2 distinct populations can be identified who are at high risk for renal allograft loss: a younger, nondiabetic patient group who develops GF due to alloimmunity and an older, more commonly diabetic population who develops DWFG and GF due to a mixture of causes—many nonalloimmune. Individualized management is needed to improve long-term renal allograft survival in the latter group.